A cross-border healthcare network to cure childhood cancers
Children with cancer deserve the best possible healthcare, wherever it may be found, writes Ruth Ladenstein.
European Reference Networks | Photo credit: SIOPE
Excellent European healthcare centres are renowned across the world for their expertise in treating paediatric malignancies.
However, at the same time some European countries lack the resources and highly-specialised know-how required to ensure the correct implementation of state-of-the art treatment protocols.
Children and adolescents with cancer deserve the best possible healthcare, no matter where they live.
We at the European Society for Paediatric Oncology (SIOPE) believe that it’s not only access to standard care and cure rates for all paediatric cancer types that should improve, but that the best possible quality of life for long-term survivors should be ensured across the whole region.
We have been at the forefront of this fight against health inequalities in Europe for many years: first with our electoral Manifesto in 2014, then by pursuing the objective “Equal Access” in our central document ‘Strategic Plan – A European Cancer Plan for Children and Adolescents’, and finally by successfully structuring a European Reference Network for paediatric oncology (ERN PaedCan).
The European Commission established 24 “European Reference Networks” (ERNs) for rare diseases with the aim to establish disease specific reference centres serving as hubs of knowledge and research.
Through treating patients at expert centres and transferring knowledge, patients from all member states will have access to subsequent treatment facilities where necessary. Disease-specific ERNs will help them make informed choices by providing clear information regarding access, quality, safety and reimbursement for treatments received in another EU country.
The foundation of the ERN PaedCan network was laid by the ExPO-r-Net project (European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment), that brought together more than 60 centres specialised in paediatric oncology clinical research, treatment and care.
In December 2016, the board of EU member states formally approved the resulting ERN PaedCan, which will officially kick-off 29-30 June in Brussels, Belgium.
This incredible result has been achievable thanks to the great team effort and the strong commitment of all ExPO-r-Net partners, who managed to consolidate the preconditions for this large multinational network.
By improving interoperability and implementing eHealth technologies that will facilitate their lives, this ERN concretely means more treatment options and less red tape for young patients and their families.
Cancer is a life-threatening disease, and there’s a long way to go to overcome inequalities and ensure safer and good quality treatment across EU borders.
We are confident however that this ERN will facilitate the existing structures in their provision of highly specialised, accessible and cost-effective cross-border healthcare to all childhood cancer patients.
SIOPE and the paediatric haemato-oncology community stress their willingness to make this important initiative work in the long term, for a future where all children and adolescents with cancer can be cured.
This content is published by the Parliament Magazine on behalf of our partners.
Eva Maydell interview, Bulgarian EU Council Presidency Preview, ITER, 5G & Artificial Intelligence, Brexit breakthrough, Afrophobia, Inland waterways, EU-Israel, Aviation, 5...
It is important to shed more light on the social impact of rare diseases, writes Françoise Grossetête.
Dimitris Avramopoulos interview, Future of Agriculture, Medical Devices, AI and Robotics, Future Farming, EU-Africa, Space Strategy, Inland waterways, Year of Cultural Heritage, EU...
There's a conflict of interest at the heart of post-authorisation vaccine evaluation research, argues Jim McMenamin.
ADPKD treatment could set the standard for tackling complex genetic conditions, argue Tess...
Taking healthcare home is key to delivering sustainable treatment, writes Paul Leeflang.